[生物书合集].Advances.in.Clinical.TBiostatisti

生& - 12 Babb and Rogatko the opinions of the investigators prior to the onset of the trial It is through the prior that

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
the opinions of the investigators prior to the onset of the trial. It is through the prior that information from previous trials, clinical and preclinical experience, and medical theory are incorporated into the analysis. The prior distribution should be concentrated in some mean- ingful way around a prior guess ˆ N 0 (provided by the clinicians), yet it should also be sufficiently diffuse as to allow for dose escalation in the absence of dose limiting toxicity (Gasparini and Eisele, 2000). We note that several authors (e.g., Tsutakawa, 1972, 1975) have be taken to be a uniform distribution on a suitably defined interval (Babb et al., 1998) or a normal distribution with appropriately large variance (Gatsonis and Greenhouse, 1992). Example: 5-FU Trial (continued) The statistical goal of the trial was to determine the MTD of 5-FU when administered in conjunction with 20 mg/m 2 leucovorin and 0.5 mg/ m 2 topotecan. The dose-toxicity model used to design the trial was that given by Eq. (3), reparameterized in terms of r =[ g U 0 ]. Preliminary
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 06/13/2011 for the course PHYSICS 101 taught by Professor Shu during the Spring '11 term at FIU.

Ask a homework question - tutors are online